What is Obesema 0.25mg Injection?
Obesema 0.25mg is a weekly injectable medicine containing the active ingredient semaglutide, which is a GLP-receptor agonist.
The package comprises injectable semaglutide solution for use by the subcutaneous route once a week according to the instructions for use. It helps control appetite and regulate blood glucose levels by activating GLP-1 receptors in the body.
The drug is prescribed in combination with other treatment modalities, such as reduced-energy diet and increase of daily physical activity.
Australian TGA information for semaglutide supports its use for chronic weight management in appropriate adults.
What is Obesema 0.25mg Used For?
Obesema 0.25mg contains semaglutide, which may be prescribed as part of a treatment plan for weight management in eligible patients.
Semaglutide can help:
- Reduce appetite
- Support lower food intake
- Improve feelings of fullness
- Support weight loss and weight maintenance
- Help with blood glucose regulation in appropriate diabetes treatment
For weight management, Australian product information describes semaglutide as an addition to a reduced-energy diet and increased physical activity.
How Does Obesema 0.25mg Work?
Semaglutide is effective as it activates theGLP-1 receptors (GLP-1), which play a role in the regulation of appetite and blood glucose levels.
One of the mechanisms of action is stimulation of insulin release in the case of elevated blood glucose levels, whereas glucagon release is suppressed. Moreover, the emptying of gastrics is slowed which, by the way, all can contribute to the regulation of blood glucose and also decrease food intake as an effect of reduced appetite.
How to Use Obesema 0.25mg
Obesema 0.25mg is given as a subcutaneous injection, meaning it is injected under the skin rather than into a vein or muscle.
Australian semaglutide product information lists the abdomen, thigh or upper arm as suitable injection areas. It is administered once weekly and can be taken at any time of day, with or without meals.
Use the injection device only as instructed by your healthcare professional. Read the instructions supplied with the specific product before using it.
Obesema 0.25mg Dosage
0.25mg once weekly is the starting dose in the Australian Wegovy dosing schedule for semaglutide used for chronic weight management. The dose is gradually increased to help reduce gastrointestinal symptoms.
The Australian schedule describes:
- Weeks 1–4: 0.25mg once weekly
- Weeks 5–8: 0.5mg once weekly
- Weeks 9–12: 1mg once weekly
- Weeks 13–16: 1.7mg once weekly
- Maintenance: 2.4mg once weekly
If significant gastrointestinal symptoms occur, dose escalation may be delayed until symptoms improve.
Do not change the dose yourself. The appropriate dose and escalation schedule should be determined by your doctor.
Possible Side Effects of Obesema 0.25mg
Semaglutide can cause digestive side effects, particularly while the dose is being increased.
Common effects include:
- Nausea
- Diarrhoea
- Constipation
- Vomiting
- Abdominal pain
- Headache
- Dizziness
- Fatigue
- Injection-site reactions
According to the Australian product information, nausea, diarrhoea, constipation and vomiting are the most common side effects being reported.
Vomiting or diarrhoea leading to dehydration is a risk if they are severe or persistent. Severe abdominal pain is another reason to seek treatment promptly because it could be a sign of acute pancreatitis associated with GLP-1 receptor agonists.
Precautions While Using Obesema 0.25mg
Tell your doctor about the conditions you have and which medicines you take before starting semaglutide.
Extra caution might be needed if you suffer from, or suffered from, kidney or liver disease, pancreatitis or gastrointestinal problems. Severe gastrointestinal symptoms can cause dehydration which in turn could affect kidney function.
Your doctor will probably have to change your prescription of insulin and/or sulfonylurea as the combination is likely to lower blood glucose further.
It is not recommended to use semaglutide during pregnancy. According to the Australian leaflet, it is advised to cease this medicine at least 2 months before pregnancy due to the drug’s long half-life. It is also not recommended for use during lactation.
Obesema 0.25mg and Other Medicines
Semaglutide works by slowing down the process of gastric emptying which is the movement of the stomach’s content into the duodenum (small intestine). This effect of the medicine may interfere with the absorption of some substances (e.g., medications, supplements and etc.) taken orally.
Making disclosure to your physician regarding your current use of pharmaceutical products or natural remedies (e.g., supplements and herbal treatments) can be very helpful in the management of your health.
In case you’re already receiving treatment with another GLP-1 receptor agonist, never use it together with semaglutide unless your doctor clearly approves such a combination.
How Should Obesema 0.25mg Be Stored?
Australian semaglutide information states that the injection should be stored in a refrigerator at 2°C to 8°C, protected from light and not frozen. It should be kept away from the cooling element of the refrigerator.
The Australian Wegovy product information also states that it may be stored unrefrigerated for up to 28 days at temperatures not above 30°C for that specific product.
For Obesema specifically, follow the storage instructions printed on the product packaging.
FAQs
Why is Obesema 0.25mg used as the starting dose?
The lower starting dose allows the body to adjust to semaglutide before the dose is gradually increased. Australian product information uses a step-by-step escalation schedule to reduce the likelihood of gastrointestinal symptoms.
Can I change the injection site from week to week?
Yes. Australian semaglutide information allows injection into the abdomen, thigh or upper arm, and the injection site can be changed without adjusting the dose.
What should I do if I miss my Obesema 0.25mg dose?
For the Australian Wegovy schedule, a missed dose should be taken as soon as possible within 5 days. If more than 5 days have passed, the missed dose should be skipped and the next dose taken on the regular day.
Can Obesema 0.25mg be used before surgery?
Tell your doctor, surgeon or anaesthetist that you are taking semaglutide before surgery or deep sedation. GLP-1 medicines can delay stomach emptying, which may create additional considerations during anaesthesia. The TGA has specifically issued safety information about this risk.
What if I experience severe stomach pain while using Obesema 0.25mg?
Severe or persistent abdominal pain should not be ignored. Acute pancreatitis has been reported with GLP-1 receptor agonists. Seek medical attention if you develop symptoms that could indicate pancreatitis.
Medical Disclaimer
This information is for educational purposes only and does not replace advice from a doctor or pharmacist. Obesema 0.25mg contains semaglutide and should be used only under appropriate medical supervision. Always follow the prescription and instructions supplied with your specific product.
References
Australian Healthdirect – Healthdirect – Wegovy (Semaglutide)
Australian TGA – TGA – Wegovy 0.25mg ARTG Information
